key: cord-0307420-5gx0khju
authors: Su, Fang-Yi; Zhao, Qingyang; Dahotre, Shreyas N.; Gamboa, Lena; Bawage, Swapnil Subhash; Silva Trenkle, Aaron D.; Zamat, Ali; Phuengkham, Hathaichanok; Ahmed, Rafi; Santangelo, Philip J.; Kwong, Gabriel A.
title: In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles
date: 2021-10-15
journal: bioRxiv
DOI: 10.1101/2021.10.14.464373
sha: 8fb339eb3b51d68ac9185f566dd31284d3733f76
doc_id: 307420
cord_uid: 5gx0khju

Simultaneous delivery of mRNA to multiple populations of antigen (Ag)-specific CD8+ T cells is challenging given the diversity of peptide epitopes and polymorphism of class I major histocompatibility complexes (MHCI). We developed Ag-presenting nanoparticles (APNs) for mRNA delivery using pMHCI molecules that were refolded with photocleavable peptides to allow rapid ligand exchange by UV light and site-specifically conjugated with a lipid tail for post-insertion into preformed mRNA lipid nanoparticles. Across different TCR transgenic mouse models (P14, OT-1, Pmel), UV-exchanged APNs bound and transfected their cognate Ag-specific CD8+ T cells equivalent to APNs produced using conventionally refolded pMHCI molecules. In mice infected with PR8 influenza, multiplexed delivery of UV-exchanged APNs against three immunodominant epitopes led to ~50% transfection of a VHH mRNA reporter in cognate Ag-specific CD8+ T cells. Our data shows that UV-mediated peptide exchange can be used to rapidly produce APNs for mRNA delivery to multiple populations of Ag-specific T cells in vivo. Teaser Light-induced rapid production of antigen-presenting nanoparticles for mRNA delivery to multiple virus-specific T cell populations.

Antigen (Ag)-specific CD8+ T cells express T cell receptors (TCRs) that recognize processed peptide antigens bound to major histocompatibility complex class I (MHCI) molecules expressed on the cell surface. The TCR-pMHCI interaction forms the basis for the exquisite specificity of CD8+ T cell recognition and their cytotoxic activity against target cells bearing cognate pMHCI antigens. This central mechanism has driven increasing interest in delivery approaches that can target and modulate T cells for immunotherapy. Recent studies include delivery of immunomodulatory molecules (e.g., TGFβ inhibitors) using nanoparticles decorated with antibodies against T cell surface markers, including CD3 and PD-1, to enhance effector functions within the tumor microenvironment (1-4). Programming endogenous CD3+ or CD8+ T cells with polymer/lipid nanoparticles loaded with nucleic acids [e.g., CD45 siRNA, chimeric antigen receptor (CAR)-encoded DNA] has shown potential to silence target genes in T cells or for in situ manufacturing of CAR T cells (5) (6) (7) (8) (9) . To target Ag-specific T cells in vivo, strategies include engineered human pMHCI (human leukocyte antigen, HLA)-Fc fusion dimers to expand human papillomavirus (HPV)-specific CD8+ T cells against HPV-associated malignancies (10) or track virus-specific CD8+ T cells by immuno-PET imaging (11) ; tumor-targeting antibodies to deliver viral peptides that are cleaved by tumor proteases and then loaded onto MHCI on the tumor cell surface to redirect virus-specific T cells against tumors (12, 13) ; and nanoparticles decorated with pMHC class II molecules to reprogram autoantigen-reactive CD4+ T cells into diseasesuppressing regulatory T cells (14, 15) . These studies highlight the broad applications of in vivo delivery to Ag-specific T cells.

Despite considerable interest, however, multiplexed delivery to distinct populations of Agspecific T cells remains challenging owing to the complexity of the immune response. For example, over 500 SARS-CoV-2 CD8+ T cell epitopes restricted cross 26 HLA class I alleles have been described so far (16). Conventionally, pMHCI molecules are expressed by individual refolding reactions to assemble three components -an invariant light chain, a polymorphic heavy chain, and a peptide ligand -into the heterotrimeric structure of endogenous pMHCI molecules (17) . This serial process precludes production of large pMHCI libraries (18) until the development of peptide exchange strategies mediated by UV light (17, 19) , temperature (20) , dipeptides (21) , or chaperone proteins (22) . With UV light-mediated peptide exchange, the heavy and light chains are refolded with a sacrificial peptide containing a photolabile group, such that upon photocleavage by UV light, the sacrificial peptide dissociates to allow an exchange peptide to bind to the MHCI presentation groove (17, 19) . For a particular MHC allele, a single batch of UVsensitive pMHCI molecules can be conventionally refolded and then used to produce 100s of pMHCI molecules carrying different peptides in one step. For example, pMHCI tetramer libraries with >1,000 peptide specificities have been described for the detection of neoAg-specific T cells (23) .

Here we developed Ag-presenting lipid nanoparticles (APNs) synthesized using UV lightmediated ligand exchange for multiplexed mRNA delivery to influenza-specific CD8+ T cells (Fig.   1) . We used UV light-mediated ligand exchange to produce a panel of pMHCI molecules from a sacrificial pMHCI precursor that was site-specifically modified with a lipid tail. This allowed postinsertion after peptide exchange to preformed lipid nanoparticles (LNPs) -which was formulated based on a similar MC3-based composition as the first FDA-approved siRNA drug (Onpattro®) (24) -encapsulating a model mRNA reporter encoding a camelid VHH antibody (25) . We found that APNs decorated with conventionally refolded or peptide-exchanged pMHCI molecules targeted and transfected Ag-specific CD8+ T cells in multiple TCR transgenic mouse models in vivo (P14, Pmel-1 and OT-1) regardless of the MHC allotype (H2-D b for P14 and Pmel, H2-K b for OT-1). In a mouse model of recombinant influenza A viral infection (A/Puerto Rico/8/34 H1N1 modified with GP33 antigen, abbreviated as PR8-GP33), intravenously administration of a 3-plex cocktail of peptide-exchanged APNs (NP366/D b , PA224/D b , GP33/D b ) resulted in the simultaneous transfection of the top three immunodominant PR8-GP33 specific T cell populations that was significantly more efficient compared to other major cell populations in the spleen and liver. Our data shows that UV light-mediated peptide exchange allows for parallel production of APNs for multiplexed delivery to Ag-specific CD8+ T cells in vivo. 

The insertion of derivatives modified with lipids to pre-formed nanoparticles is a well-established approach (26) to decorate nanoparticles with ligands that are stabilized by hydrophobic interactions. For example, post-insertion is commonly used to PEGylate liposomes or LNPs using PEG polymers derivatized with lipid tails (27) . We therefore first sought to express recombinant pMHCI molecules with a site-specific handle for conjugation of a lipid such that the complex could serve as the starting point for peptide exchange prior to post-insertion to LNPs (Fig. 1A) . We expressed and refolded the lymphocytic choriomeningitis virus (LCMV) antigen GP33/D b (KAVYNFATM/D b ) with a C-terminal cysteine in the heavy chain to prevent disruption of native disulfide bonds (28) and retain proper pMHCI orientation for TCR recognition (29) . These were then reacted with DSPE-PEG2000-maleimide to generate lipid-modified GP33/D b molecules. In parallel, we synthesized MC3-based LNPs encapsulating eGFP mRNA by microfluidic mixers that were characterized by an average diameter of 93.85 nm and a zeta potential of -30.20 ± 0.5 mV by dynamic light scattering ( Fig. S1A and S1B) . Post-insertion of lipid-modified GP33/D b pMHCI molecules did not appreciably increase LNP size nor alter the zeta potential (107.9 ± 7.34 nm and -22.73 ± 4.7 mV respectively) ( Fig. S1B and S1C) . We also assessed eGFP mRNA concentration using the Ribogreen assay and found that bare LNPs and APNs were comparable (80.20 ± 0.50% to 73.62 ± 0.58%, respectively) (Fig. S1C) .

We next tested whether GP33/D b APNs can selectively bind to their cognate CD8+ T cells isolated from TCR transgenic P14 mice whose CD8+ T cells express a TCR that specifically recognizes the LCMV GP33/D b antigen ( Fig. 2A) (30) . We found that GP33/D b APNs bound to ~ 97% of P14 CD8+ T cells whereas non-cognate GP100/D b (KVPRNQDWL/D b ) APNs showed minimal staining (3.22%) (Fig. 2B) . We further tested APN binding using H2-K b restricted OVA/K b (SIINFEKL/K b ) APNs and observed similar Ag-specific binding when co-incubated with their cognate CD8+ T cells isolated from OT-1 transgenic mice compared to non-cognate NS2/K b (RTFSFQLI/K b ) APNs (Fig. 2C) . We next investigated whether the binding of APNs to T cells would induce internalization by T cells given that pMHCI multimers are known to be rapidly taken up by T cells through TCR clustering and receptor-mediated endocytosis at physiological temperatures (31) . To do this, we studied the fate of APNs after engaging cognate T cells at 37°C compared to 4°C, which is typically used for pMHCI multimer staining to minimize T cell activation and TCR internalization (32) . We incubated DiD-labeled OVA/K b APNs with OT-1 CD8+ T cells at 4°C and 37°C, followed by an acidic wash to strip un-internalized APNs bound to the TCRs on T cell surface. We found that DiD fluorescence decreased for cells incubated at 4°C, indicating that APNs remained on the cell surface prior to acid wash ( Fig. 2D and 2E) . For cells treated at 37°C, however, we observed no change in fluorescence, suggesting efficient T cell internalization of APNs. By contrast, we found no binding and internalization of non-cognate GP100/D b APNs by OT-1 CD8+ T cells under all conditions (Fig. 2E) . To determine whether pMHCI-induced TCR internalization could result in functional mRNA delivery to T cells, we incubated P14 splenocytes with GP33/D b APNs loaded with eGFP mRNA. We observed a dose-dependent eGFP expression by APN-transfected CD8+ T cells [Mean fluorescent intensity (MFI): 397 and 506 for 1 µg and 2 µg mRNA doses, respectively] in contrast to splenocytes treated with PBS (MFI: 153) or free mRNA (MFI: 118) (Fig. 2F) . Collectively, these results demonstrate that cognate APNs target, bind and induce T cell uptake for functional mRNA delivery in vitro. ****P < 0.0001 between OVA/K b APN treatment with and without acid treatment at 4°C; n.s. = not significant where p = 0.61 between OVA/K b APN with and without acid treatment at 37 °C; two-way ANOVA and Sidak post-test and correction. All data are means ± SD; n =3 biologically independent wells. (F) eGFP mRNA expression in P14 CD8+ T cells after co-incubation with free-form eGFP mRNA or eGFP mRNA loaded in GP33/D b APNs for 24 hr.

We next quantified in vivo biodistribution and transfection efficiency of GP33/D b APNs in TCR transgenic P14 mice (Fig. 3A) . We tested functional delivery to major organs using APNs loaded with firefly luciferase (Fluc) mRNA ( Fig. 3B and C) and found significantly higher luminescence in the spleens isolated from mice treated with GP33/D b APNs compared to non-cognate GP100/D b APNs. Notably, no significant difference was observed in the other major organs between the two groups. To quantify delivery to T cells, we harvested P14 splenocytes 24 hours after infusion of DiD-labeled APNs encapsulating VHH mRNA and observed that cognate GP33/D b APNs targeted >95% of P14 CD8+ T cells while GP100/D b APN controls resulted in <2% binding as quantified by DiD fluorescence (Fig. 3D) . To quantify functional delivery, we stained for surface expression of VHH and found that GP33/D b APNs resulted in significantly higher transfection efficiency compared to its non-cognate counterpart (~40% versus <2% respectively, Fig. 3E and F) . Notably, we observed negligible transfection (< 2%) of CD8splenocytes in mice treated with either GP33/D b APNs or GP100/D b APNs. Combined with the results we observed at the organ level by IVIS imaging (Fig. 3B and C) , our data suggested that the observed Fluc luminescence in the spleen was mainly from the transfection of cognate CD8+ splenocytes. We further confirmed our results in a different model using Pmel mice that have been engineered to express the cognate TCR against GP100/D b . Similar to our results in P14 mice, we observed ~30-40% in vivo transfection of Pmel CD8+ splenocytes treated with GP100/D b APNs 10 compared to ~3% transfection with GP33/D b non-cognate APNs (Fig. S2) . Together, these results demonstrate that APNs enable T cell targeting and functional mRNA delivery in an antigenspecific manner. ****P < 0.0001 between PBS and GP33/D b APNs as well as between GP100/D b APNs and GP33/D b APNs; one-way ANOVA and Tukey post-test and correction. All data are means ± SD; n = 5 biologically independent mice.

Sacrificial peptides that contain a photolabile amino acid and stabilize the MHCI complex during refolding have been previously developed for prevalent alleles including H2-K b and H2-D b in mice (17, 33) . Therefore, we validated UV-mediated peptide exchange by comparing staining of P14 splenocytes using fluorescent GP33/D b tetramers where the pMHCI monomers were either produced by peptide exchange from ASNENJETM/D b (J represents photocleavable amino acid) or conventionally refolded. We found that both tetramers stained >95% of CD8+ P14 splenocytes, whereas non-cognate GP100/D b tetramers produced by refolding or UV exchange resulted in minimal binding (Fig. S3) . We further tested UV-exchanged tetramers to detect endogenous immune responses where T cells have a broad range of antigen-specificity and binding affinities to their cognate antigens. To do this, we used the well-characterized mouse model of influenza (34-37) which served as a positive control epitope. We produced a panel of pMHCI tetramers against these 6 epitopes by peptide exchange (Fig. 4A and 4B ) (38) and validated Ag-specific splenic T cell responses 10 days post-infection (Fig. 4C) (37, 39) . We next sought to integrate UV-exchange for APN production. To do this, we synthesized a panel of three UV-exchanged APNs inserted with GP33/D b , GP100/D b , and OVA/K b pMHCI molecules to compare with APNs inserted with pMHCI molecules synthesized using the conventional refolding protocol. In splenocytes isolated from three strains of transgenic mice (P14, Pmel, and OT-1), we found that cognate UV-exchanged APNs bound to CD8+ T cells similar to the folded APNs (Fig. 4D) . By contrast, we only observed minimal background staining from the non-cognate control APNs. Last, we tested whether the UV-exchanged APNs can target and transfect virus-specific T cells in vivo using PR8-infected mice. To do this, we intravenously injected DiD-labeled PA224/D b APNs to PR8-infected mice (37, 39) . At 24 hr after injection, we found that, consistent with the in vitro staining results (Fig. 4D) , both folded and UV-exchanged PA224/D b APNs targeted ~80% of PA224-specific T cells (Fig. 4E) and resulted in comparable transfection efficiency of the model VHH mRNA (Fig. 4F) .

Antibodies against T cell surface markers, including CD3 and CD8, have been used to target polymeric nanoparticles to T cells in vivo irrespective of Ag-specificity (40, 41) . We therefore examined the ability of APNs to transfect virus-specific T cells compared to non-cognate cell populations (Fig. 5A) . We focused our analysis on liver and spleen as these were the major organs that showed APN accumulation after intravenous administration (Fig. S4) . Flow cytometry

macrophages, monocytes, PA224+ flu-specific CD8 T cells, non-cognate PA224-CD8 T cells, Kupffer cells, hepatocytes, and endothelial cells] revealed that APNs preferentially transfected flu virus-specific T cells (PA224+ CD8 T cells, 59.46 ± 11.81%) compared to non-cognate T cells (PA224-CD8 T cells, 2.63 ± 2.17%), which comprise a population diversity of approximately 10 6 to 10 8 (Fig. 5B) (42) . As anticipated, transfection was also observed by the reticuloendothelial system -including monocytes and macrophages in the spleen and Kupffer cells in the liver -but at significantly lower transfection efficiency than that of PA224-specific CD8 T cells (****P < 0.0001). Compared to cohorts that received PBS, mice that were given folded or UVexchanged PA224/D b APNs resulted in similar transfection levels across all cell populations studied, supporting their equivalency.

To demonstrate simultaneous transfection of distinct Ag-specific T cells populations in vivo, we administered a mixture of DiD-labeled, conventionally refolded NP366/D b and PA224/D b APNs to PR8-infected mice at a mRNA dose of 0.1 and 0.015 mg/kg for each APNs. We found that APNs specifically targeted NP366-and PA224-specific T cells in a dose-dependent manner ( Fig. S5) , whereas no detectable DiD fluorescence was observed in NP366-PA224-T cells (42) .

This resulted in a dose-dependent transfection of NP336+ or PA224+ T cells with the model VHH mRNA (Fig. 5C ) compared to minimal transfection (<5%) of NP366-and PA224-CD8+ T cells, which was consistent with our earlier observations (Fig. 5B) . Last, to demonstrate multiplexed transfection with UV-exchanged APNs, we synthesized and pooled a 3-plex panel of APNs presenting the top three immunodominant epitopes (NP366, PA224, GP33) for PR8-GP33 (Fig.   5D ). This APN library efficiently transfected the three selective clones of T cells with significantly higher expression of the model VHH protein than T cells in mice treated with PBS (Fig. 5E) .

PA224/D b APNs administrated alone ( Fig. 4F and 5B) , suggesting that the APN-mediated multiplexed transfection did not compromise the transfection efficiency in each T cell population tested. 

Ag-specific CD8+ T cells are key players in adaptive immunity and their ability to directly kill target cells expressing cognate peptide antigens restricted to MHCI presentation is being harnessed for important applications in cell therapy, vaccines, and autoimmunity (10) (11) (12) (13) (14) (15) .

Whereas previous work on delivery to T cells via antibodies against cell surface markers (CD3, CD8, etc.) show great promise, these markers are expressed by all T cells. Moreover, Ag-specific T cell responses are polyclonal (43, 44) ; for instance, across five prevalent HLA-A alleles (HLA-A*01:01, HLA-A*02:01, HLA-A*03:01, HLA-A*11:01, and HLA-A*24:02) over 110 flu-specific peptide epitopes have been identified for human influenza A virus (PR8) (45) . Therefore, we developed APNs for multiplexed mRNA delivery to Ag-specific T cells using UV-mediated peptide exchange to expedite production of APNs against a panel of peptide epitopes. Our in vivo data using PR8-infected mice showed that APNs with UV-exchanged pMHCI molecules transfected PA224-specific T cells equivalently to APNs synthesized with conventionally folded pMHCI molecules. This allowed us to construct a 3-plex APN library using UV-mediated peptide (17, 48, 49) . Therefore, APNs are amenable to other pMHCI molecules, including HLA expressed by human CD8 + T cells. The capability of APNs in transfecting multiple virus-specific T cell populations may be used to induce in vivo proliferation of virus-specific T cells to treat virus-mediated cancers. For instance, a fusion protein composed of dimerized pMHCI and IL-2 has been developed to expand HPV16 E7 11-20 -specific CD8+ T cells to treat HPV-mediated cancers (10) , and a recent study suggests that HPV-specific T cells recognizing peptide epitopes derived from HPV E2 and E5 proteins should also be considered to elicit maximal tumor-reactive CD8+ T cell responses against HPV-positive head and neck cancer (50) .

Other than CD8+ T cells, it may be possible to expand the transfection capability of APNs to CD4 + T cells by generating APNs with pMHC class II (pMHCII). For example, Ag-specific CD4 + Treg cells are capable of suppressing pathogenic autoimmunity, and therefore prior studies have developed pMHCII-functionalized nanoparticles to expand Ag-specific Tregs through pMHC-TCR interaction for the treatment of autoimmune diseases (14, 15) . However, this is likely more challenging as binding of class II-bound peptides is less stable compared to that of class I-bound peptides (51) , and the interaction between the pMHCII and CD4 + T cells is weaker than that between the class I counterpart and CD8+ T cells (52) . Taken together, our data support that the use of APNs for multiplexed mRNA delivery to virus-specific T cells, which can potentially be expanded to transfect broader antigen-specific T cell subsets. 

Peptides used for pMHC refolding were synthesized in housed using the Liberty Blue Peptide Synthesizer (CEM) and validated using LC-MS (Agilent). To generate pMHC molecules for bioconjugation, codon-optimized gBlocks for H2-D b and H2-K b β2m were purchased from IDT and cloned into pET3a vectors (Novagen). H2-Db and H2-Kb genes were engineered with a Cterminal cysteine by site-directed mutagenesis (NEB), and pMHC molecules were expressed and refolded as described previously (19) . 

The sizes of APNs in PBS were measured by dynamic light scattering with Malvern nano-ZS Zetasizer (Malvern). Final lipid concentration was quantified using a phospholipid assay kit (Sigma). The concentration of conjugated pMHCI was determined by BCA assay kit (Sigma). The mRNA encapsulation efficiency was quantified by Quant-iT RiboGreen RNA assay (Life Technology) as previously described (7). Briefly, 50 µl of diluted APNs was incubated with 50 µl of 2% Triton X-100 (Sigma-Aldrich) in TE buffer (10 mM Tris-HCl, 20 mM EDTA) in a 96-well fluorescent plate (Costar, Corning) for 10 mins at 37 °C to permeabilize the particle. Then, 100 µl of 1% Ribogreen reagent in TE buffer was added into each well, and the fluorescence (excitation wavelength 485nm, emission wavelength 528 nm) was measured by plate reader (Biotek). 

OT-1 CD8+ T cells were isolated as described above and incubated with OVA/K b , or GP33/D b APNs at 10 µg/ml and αCD8 mAb (clone 53-6.7, BioLegend) at 4 or 37°C for 30 min. Cells were washed with FACS buffer, and a portion of stained cells was analyzed on a BD Accuri C6. The remaining cells were incubated in an acid wash solution (0.5 M NaCl + 0.5 M acetic acid, pH 2.5) for 5 min to strip cell surface proteins as described previously before reanalysis on a BD Accuri C6 (56) .

P14 TCR transgenic mice were injected intravenously with GP33/D b or GP100/D b APNs loaded with mRNA encoding firefly luciferase (0.1 mg/kg). Organs were harvested 6 h after injection and incubated in PBS on ice prior to IVIS analysis. Organs were soaked in D-luciferin solution (2 mM luciferin) in PBS for 5 min. After 5-min incubation, bioluminescence images were collected with a Xenogen IVIS Spectrum Imaging System (Xenogen, Alameda, CA). Same type of organs was separated from other organs and imaged together (i.e., spleens from all treatment groups were imaged together).

P14 or Pmel TCR transgenic mice were injected intravenously with GP33/D b or GP100/D b APNs loaded with GPI-anchored Camelid VHH antibody mRNA (0.2 mg/kg). Splenocytes were harvested 24 h after injection and stained against αCD8 mAb (clone 53-6.7, BioLegend) and anti-Camelid VHH antibody (Genescript) on ice for 30 min. Cells were washed three times with 1 mL FACS buffer before analysis on a BD Accuri C6. Mice splenocytes were harvested 24 h later and stained against αCD8 mAb (clone 53-6.7, BioLegend), anti-Camelid VHH antibody (clone 96A3F5, Genescript), and pMHC tetramers (streptavidin 2 µg/ml) on ice for 30 min. Epitope pMHC tetramers for staining were synthesized in house by mixing biotinylated pMHC with fluorescently labelled streptavidin at a 4:1 molar ratio (19) . Cells were washed three times with FACS buffer before analysis on BD Accuri C6. All flow data in this study were analyzed with FlowJo v.10 (TreeStar). 

Significant differences between control and treatment groups were determined by various statistical analyses. Student's t test was used for two groups comparison. One-way analysis of variance (ANOVA) was used for multiple groups comparison. Two-way ANOVA was used when there were subgroups in each group. Data represent means ± SD in each figure and table as indicated. Statistical analyses were performed using GraphPad Prism 8.0.2 software (GraphPad Software). *P < 0.05, **P < 0.005, ***P < 0.0005, and ****P < 0.0001.

In vivo targeting of adoptively transferred T-cells with antibody-and cytokine-conjugated liposomes

T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity

Enhancing adoptive cell therapy of cancer through targeted delivery of small-molecule immunomodulators to internalizing or noninternalizing receptors

Targeting small molecule drugs to T cells with antibody-directed cellpenetrating gold nanoparticles

Systemic gene silencing in primary t lymphocytes using targeted lipid nanoparticles

In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers

A modular platform for targeted RNAi therapeutics

In vitrotranscribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo

Interfacing biomaterials with synthetic T cell immunity

CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances tumor antigen-specific T-Cell activation for the treatment of hpv16-driven malignancies

In vivo detection of antigen-specific CD8+ T cells by immunopositron emission tomography

Antibody-mediated delivery of viral epitopes to tumors harnesses CMVspecific T cells for cancer therapy

Sensitization of Tumors for Attack by Virus-Specific CD8+ T-Cells Through Antibody-Mediated Delivery of Immunogenic T-Cell Epitopes

Expanding antigen-specific regulatory networks to treat autoimmunity

Peptide-MHC-based nanomedicines for autoimmunity function as T-cell receptor microclustering devices

Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases

Design and use of conditional MHC class I ligands

Antigen identification for orphan T Cell receptors expressed on tumorinfiltrating lymphocytes

Generation of peptide-MHC class I complexes through UV-mediated ligand exchange

A flexible MHC class I multimer loading system for large-scale detection of antigen-specific T cells

Dipeptides catalyze rapid peptide exchange on MHC class I molecules

High throughput pMHC-I tetramer library production using chaperonemediated peptide exchange

Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes

Multi-discipline review: patisiran. Population PK and/or PD analyses

Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection

Poly(ethylene glycol)-modification of the phospholipid vesicles by using the spontaneous incorporation of poly(ethylene glycol)-lipid into the vesicles

Delivery of oligonucleotides with lipid nanoparticles

Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development

Site-selective orientated immobilization of antibodies and conjugates for immunodiagnostics development

In vivo selection of a lymphocytic choriomeningitis virus variant that affects recognition of the GP33-43 epitope by H-2Db but not H-2Kb

Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent

Phenotypic analysis of antigen-specific T lymphocytes

Discovery of CD8+ T cell epitopes in Chlamydia trachomatis infection through use of caged class I MHC tetramers

Qualitatively different memory CD8+ T cells are generated after lymphocytic choriomeningitis virus and influenza virus infections

The PD-1 Pathway Regulates Development and Function of Memory CD8 T Cells following Respiratory Viral Infection

Microbiota regulates immune defense against respiratory tract influenza A virus infection

Cooperativity between CD8+ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity

Immunization with live attenuated influenza viruses that express altered NS1 proteins results in potent and protective memory CD8+ T-cell responses

Quantification of epitope abundance reveals the effect of direct and crosspresentation on influenza CTL responses

Progress and challenges towards targeted delivery of cancer therapeutics

In Vivo T Cell-Targeting Nanoparticle Drug Delivery Systems: Considerations for Rational Design

The many important facets of T-cell repertoire diversity

An Unexpectedly Large Polyclonal Repertoire of HPV-Specific T Cells Is Poised for Action in Patients with Cervical Cancer

Dissection of T-cell antigen specificity in human melanoma

National Institute of Allergy and Infectious Diseases

Differential evolution and stability of epitope-specific CD8(+) T cell responses in EBV infection

Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers

Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7

A simple and rapid method for quality control of major histocompatibility complex-peptide monomers by flow cytometry

Functional HPV-specific PD-1+ stem-like CD8 T cells in head and neck cancer

Systematically benchmarking peptide-MHC binding predictors: From synthetic to naturally processed epitopes

Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4+ T cells

Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes

A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs

Conventional versus stealth lipid nanoparticles: Formulation and in vivo fate prediction through FRET monitoring

Synthetic antigen-presenting cells for adoptive t cell therapy

DNA-Barcoded pMHC tetramers for detection of single antigen-specific T Cells by digital PCR

Individually addressable and dynamic DNA gates for multiplexed cell sorting

Modular Nucleic Acid Assembled p/MHC Microarrays for Multiplexed Sorting of Antigen-Specific T Cells

Schematic of the generation of APNs using microfluidic mixers and post-insertion technique. (B) Uniform distribution of the synthesized bare nanoparticles (NPs) and APNs functionalized with GP33/D b APN. (C) Hydrodynamic size, polydispersity index (PDI), zeta potential, and mRNA loading of the produced NPs

Supplement figure 2. In vivo APN-mediated transfection in CD8+ splenocytes isolated from

Pmel TCR transgenic mice. ***P < 0.001 between GP33/D b APNs (non-cognate) and GP100/D b

APNs (cognate); one-way ANOVA and Tukey post-test and correction. All data are means ± SD

n = 3 biologically independent mice

Data generated or analyzed during this study and all unique materials can be made available by the corresponding author on reasonable request. flu-specific T cell population (NP366+); ****P < 0.0001; two-way ANOVA and Sidak post-test and correction. All data are means ± SD; n = 3 biologically independent mice.